Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23–24 Jun 2025 at weighted-average prices of $20.87–$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.